[31] A large study found that GLP-1 RA use was associated with lower risk of developing immune-mediated inflammatory diseases in patients with type 2 diabetes or obesity, suggesting a potential protective effect in some cohorts.[42] What the science is showing is potential for improvements: GLP-1RAs reduce blunt activation in fibroblast-like synoviocytes and improve joint inflammation and metabolic parameters in rheumatoid arthritis models and small human cohorts.[26][29][25] [31] Early clinical studies and case series in RA patients (especially those with coexisting type 2 diabetes or obesity) reported reduced disease activity scores (DAS28), lower C-reactive protein and erythrocyte sedimentation rate levels, fewer swollen joints, and diminished morning stiffness during GLP-1RA treatment, along with the expected weight reduction and improved insulin sensitivity.[31] Psoriasis showed improved PASI scores and quality-of-life metrics in patients with T2DM and psoriasis, alongside reductions in lesional skin and peripheral TNF-producing monocytes.[26] Case series show meaningful skin improvement.[26] In psoriasis and psoriatic arthritis , GLP-1RA therapy has been associated with improvements in inflammatory markers and disease severity indices
In short, cagrilintide adds one non-incretin appetite axis, while retatrutide stacks three metabolic signals into one molecule
Managing Appetite and Cravings During GLP-1 Discontinuation As your GLP-1 dose decreases, hunger typically returns within 12 weeks of each dose reduction step
Genetic Factors and Individual Variability in Semaglutide Response During Training Genetic variants in GLP-1 receptor signaling (GLP1R rs6923761), appetite regulation (MC4R rs17782313), and metabolic processing influence how aggressively semaglutide suppresses appetite and affects energy utilization
Moreover, the product is dairy-free and free from added sugars, artificial colours and preservatives
